Recruiting

Testing a new scan to detect multiple myeloma and measure treatment response

Plain-English translation of NCT03832127 on ClinicalTrials.gov ↗ · Source last updated June 2024 · Translation generated July 2026 · How we translate trials

Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.

What is this trial?

This trial is exploring whether a new type of imaging scan using can better detect multiple myeloma cancer in your bones and measure how well your treatment is working. Right now, doctors typically use other types of scans to find myeloma and track treatment response. This study wants to see if the new medication could give clearer, more useful pictures of your disease.

Multiple myeloma is a blood cancer that can be hard to see with standard imaging tests. Doctors need better ways to find all the cancer in your body at diagnosis and to know whether treatment is actually working. This medication may provide clearer images that help guide your care.

Do you qualify?

You likely qualify if…

you have been newly diagnosed with symptomatic multiple myeloma and are not a candidate for stem cell transplant
you are eligible for standard first-line cancer treatments according to current medical guidelines
you have measurable disease on blood tests or urine tests
you are at least 18 years old and in good enough overall health to participate
you are willing to use effective birth control during the study and for 30 days after the final scan (if you can become pregnant) or use a condom and spermicide (if you are a man with a pregnant or potentially pregnant partner)

You likely don't qualify if…

you are pregnant, breastfeeding, or unwilling to use birth control
you have severe kidney or liver problems
you have very low blood cell counts that would make the scan unsafe
you have diabetes (either type) or a serious active infection
you have a history of other cancers (except certain minor skin cancers) or active hepatitis B or C

What participation looks like

You would receive PET scans using the new medication at the start of the study to help diagnose your myeloma, and again at the end of your cancer treatment to see how well the therapy worked. The scan itself is similar to other imaging tests you may have had—you receive an injection of the radioactive medication and then lie still while a camera takes pictures. The study team will compare these new scan results with traditional scans (like standard PET or MRI) to see if the new medication provides better information.

AI-generated summary from trial data · Jul 1, 2026 · Not medical advice

Trial locations(7 sites)

France

CHU d'Angers, Angers

CHU de Brest, Brest

CHU de Caen, Caen

CHU de Nantes, Nantes

Centre Eugène Marquis, Rennes